Stocktoria
PERRIGO Co plc PRGO
PERRIGO Co plc (PRGO) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It pays a dividend yielding 11.57% (safety: safe). FY2025 revenue was $4.3B at a -33.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.55 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.209 |
| Retained earnings / assets | -0.431 |
| EBIT / assets | -0.131 |
| Equity / liabilities | 0.524 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PRGO | PERRIGO Co plc | 4/9 | -0.37 | — | -2.8% |
| JAZZ | Jazz Pharmaceuticals plc | 5/9 | 1.63 | — | +4.9% |
| ELAN | Elanco Animal Health Inc | 6/9 | — | — | +6.2% |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | 5/9 | -0.11 | 124 | +65.2% |
| BMRN | BIOMARIN PHARMACEUTICAL INC | 4/9 | 7.43 | 32.7 | +12.9% |
| UTHR | UNITED THERAPEUTICS Corp | 7/9 | 16.93 | 17.4 | +10.6% |
| ONC | BeOne Medicines Ltd. | 7/9 | 1.78 | — | +40.2% |
About PERRIGO Co plc
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
FAQ
Is PRGO financially healthy?
PERRIGO Co plc's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does PRGO pay a dividend, and is it safe?
Yes. PERRIGO Co plc pays a dividend yielding about 11.57% with a -11.2% payout ratio, rated “safe” for safety.
How profitable is PRGO?
In FY2025, PERRIGO Co plc had a net margin of -33.5% and a return on equity of -48.6%.
Is PRGO overvalued or undervalued?
PERRIGO Co plc trades at about 11.9× trailing earnings — below its 10-year norm (10-year range 26.6×–198.1×, median 74.9×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for PRGO?
The average Wall-Street price target for PERRIGO Co plc is $16.50, about 30.0% above the recent price, from 4 analysts.
Is PRGO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on PERRIGO Co plc: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone, a dividend yield of 11.57%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.